1Dept of Nuclear Medicine, Kasturba Medical College, Manipal University, India
2Dept of Medicine, Kasturba Medical College, Manipal University, India
3Dept of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, India
4Biovailability/Bioequivalence and PK Unit, Ecron Acunova, Manipal, India
The current therapy for patients with thyroid cancer is total or near to total thyroidectomy with Radio Iodine treatment. Subsequent to the thyroidectomy the patients are on Levothyroxine as a supplement therapy to maintain the Thyroid hormone levels. Levothyroxine has been considered as a narrow therapeutic index drug. In Thyroid cancer patients, radio-iodine ablation procedure causes hypothyroid state which will be further elongated by the administration of sub optimal doses and hyperthyroid symptoms with higher doses. The current study was conducted to evaluate the covariates influencing the drug concentration of levothyroxine in our target population, i.e Patient with Papillary carcinoma, undergone total thyroidectomy followed by 131I ablation and on Levothyroxine.
Levothyroxine, Population Pharmacokinetics, Papillary carcinoma
